GrantVestments™
Neta GrantVestments™ bridge the gap between straightforward philanthropic grants and for-profit investments (usually early stage).
-
They are grants in that they are used to further develop causes that that will have an important and lasting impact on humanity (including deep tech and scientific research)
-
And they are investments in that they keep economic upside if there are financial outcomes (e.g., the tech or research reaches the market
GrantVestments™ is how Neta donors deploy catalytic capital, how they engage in venture philanthropy.
Being a hybrid between grants and investments, GrantVestments™ can take many forms (recoverable grant, equity investment, royalty agreement, joint ventures, loan….), always tailor-made and optimized for the specific situation.
Catalytic Capital
Investments that are more patient, risk-tolerant, and flexible than conventional capital. Considered an essential tool for seeding, scaling, and sustaining deep tech because it provides investments that, among other things, helps jumpstart projects, building a track record that can attract investors to riskier opportunities. Catalytic capital works to unlock investments that would not otherwise be possible — expanding opportunity, strengthening communities, and fueling innovation that benefits humanity
Catalytic capital often works in conjunction with other types of funding, such as philanthropic grants, public sector funding, or traditional commercial investments. By blending different sources of capital, catalytic capital can leverage resources and maximize its impact.
Want to learn more about these GrantVestments™?
Want to see which GrantVestment™ we are currently focused on?
Please sign up!
Not ready to sign up, but still want to find out more about GrantVestments™, or maybe recommend a new GrantVestment™? Contact us and we will be happy to share more details.
GrantVestments™ We Have Done This Year
-
provided funding via a recoverable grant (with more than 1x upside) to a research institution to fund a milestone for a potential treatment for Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
-
invested via a SAFE note in a company developing a solution for sleep disorders caused by PTSD
-
invested via a limited partnership structure in a venture fund focused on pediatric healthcare